Market

Pfizer Stock Tumbles — What Test Results Say About Covid Shots In Babies


Pfizer stock reversed a six-day running spree Friday after the company reported mixed test results for its Covid vaccine in young children.




X



An independent committee said the vaccine looked favorable in children age 6 months to 2 years. But the preliminary results don’t look as promising for children age 2 to less than 5. However, there were no safety concerns — a key consideration as the Pfizer (PFE) and BioNTech (BNTX) vaccine has been tied to heart inflammation in boys and young men.

Now, Pfizer says it plans to seek authorization for its Covid vaccine as a three-dose primary series in children age 5 and younger. That news pushes Pfizer’s timeline for vaccinating the country’s youngest people out to mid-2022. The company is also testing a third dose in children age 5-17. Early data suggest a third dose could help bolster protection against the omicron variant.

But on today’s stock market, Pfizer stock sank 2.9% to 59.48. BioNTech stock, on the other hand, rose 1.3% to 287.28.

Pfizer Stock: Three-Dose Regimen Likely

Pfizer has several dosing regimens in play. The vaccine for children age 5-11 is one-third the dose level given to older children and adults. For children under the age of 5, the vaccine is one-tenth the dosage given to older children and adults.

In the pediatric studies, Pfizer is comparing the vaccine with results for people ages 16-25. The Covid shot proved about as effective in children age 6 months to 2 years. But it didn’t meet that bar — a measure known as non-inferiority — in children age 2 to under 5.

The results sent Pfizer stock diving.

Pfizer said it is also planning to study a third dose of the same shot for children age 5 to below 12. Further, the company is planning to test two dosing levels for a third shot in teens age 12-17.

Pfizer stock recently broke out of a cup base with a buy point at 51.96, according to MarketSmith.com.

Follow Allison Gatlin on Twitter at @IBD_AGatlin.

YOU MAY ALSO LIKE:

How Will Moderna Stock Weather Omicron? — And Other Questions For 2022

Johnson & Johnson Leads Dow Rout After CDC Favors Pfizer, Moderna Covid Shots

Watch IBD’s Investing Strategies Show For Actionable Market Insights

Get Timely Buy & Sell Alerts With IBD Leaderboard

Find The Best Long-Term Investments With IBD Long-Term Leaders





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *